Session Details

Speakers, titles, times, and locations of ASGCT presentations

Detailed Program

258: Validating EPI-321 Safety for FSHD: A Comprehensive Off Target Characterization Platform for Epigenetic Gene Therapies

Disclosures:   L.A. Smith: 1; Commercial Interest i.e. Company X; Epic Bio. 1; What was received? i.e. Honorarium; Salary and Equity. 1; For what role? i.e. Speaker; Employment.

Related Abstract

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.